ImmunityBio nearly doubled sales in the three months ended June 30, and still ended the period with less cash.
Revenue reached $51.2 million, up 93.9% from $26.4 million in the comparable three months a year earlier. The operating loss narrowed to $61.7 million from $71.3 million.
The balance sheet supplies a contrasting data point. Cash fell to $75.7 million from $137.7 million, while accounts receivable rose 141.7% to $53.5 million. Inventory moved the other way, dropping 70.8% to $1.9 million. Sales are growing; the cash sitting behind them is not.
That matters because the company is not yet funding itself through operations. The three-month net loss widened to $230.4 million from $92.6 million, and diluted shares rose 18.2% to 1.1 billion. ImmunityBio does not disclose a single reason for the larger net loss in the supplied filing data, but management does describe the financing problem directly.
Management’s warning is unusually plain in the latest 10-Q:
"As a result of continuing anticipated operating cash outflows as we commercialize our approved product in the U.S. and globally and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support."
ImmunityBio, 10-Q filed August 4, 2026.
In other words, the revenue increase arrives alongside a business that says additional funding or support is needed to continue. The filing does not turn that into a timetable, but it does connect the cash question to commercialization and development spending.
The company also flags what comes with expanding the product business:
"In addition, subject to obtaining regulatory approval of our other product candidates, we expect to incur significant incremental commercialization expenses for product sales, marketing, manufacturing and distribution."
ImmunityBio, 10-Q filed August 4, 2026.
That is the central tradeoff in the numbers. Revenue is now large enough to move the income statement, yet the company expects more spending if additional products receive regulatory approval. Operating losses can improve while the funding requirement remains active, especially when the cash balance is shrinking and share count is rising.
The market context adds scale, not an answer. ImmunityBio’s latest close was $7.15 on August 3, with a market capitalization of $6.6 billion and an enterprise-value-to-sales ratio of 57.3x based on its latest annual facts. The stock was down 0.3% that day, while its 12-month return stood at 190.7%. Those figures describe where the shares are after a large move, not why they moved on any particular day.
The next 10-Q’s cash balance, operating cash flow, accounts receivable, and diluted share count will clarify whether the June 30 snapshot was a temporary financing gap or the latest step in the same funding pattern.
ImmunityBio’s latest 10-Q pairs 93.9% revenue growth with a 45.0% cash decline.